Editas Medicine (EDIT) announced the FDA has accepted the company’s investigational new drug, or IND, application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10, or LCA10. With the IND acceptance, Editas Medicine has earned a $25M milestone payment from Allergan (AGN) as part of the alliance between the companies to discover and develop experimental ocular medicines targeting serious, vision-threatening diseases. Editas Medicine and its partner, Allergan Pharmaceuticals International, a wholly-owned subsidiary of Allergan, expect to enroll 10 to 20 patients in a Phase 1/2 open label, dose escalation study to evaluate the safety, tolerability, and efficacy of EDIT-101.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.